Long Term Outcome After Transjugular Intrahepatic Portosystemic Stent-shunt in Non-transplant Cirrhotics with Hepatorenal Syndrome: a Phase II Study

Overview

Journal Gut

Specialty Gastroenterology

Date 2000 Jul 18

PMID 10896924

Citations 100

Authors

K A Brensing

J Textor

J Perz

P Schiedermaier

P Raab

H Strunk

H U Klehr

H J Kramer

U Spengler

H Schild

T Sauerbruch

Affiliations

Soon will be listed here.

Abstract

Background: Recent small studies on hepatorenal syndrome (HRS) indicate some clinical benefit after transjugular intrahepatic portosystemic stent-shunt (TIPS) but sufficient long term data are lacking.

Aim: We studied prospectively feasibility, safety, and long term survival after TIPS in 41 non-transplantable cirrhotics with HRS (phase II study).

Patients And Methods: HRS was diagnosed using current criteria (severe (type I) HRS, n=21; moderate (type II) HRS, n=20). Thirty one patients (14 type I, 17 type II) received TIPS (8-10 mm) while advanced liver failure excluded shunting in 10. During follow up (median 24 months) we analysed renal function and survival (Kaplan-Meier).

Results: TIPS markedly reduced the portal pressure gradient (21 (5) to 13 (4) mm Hg (mean (SD)); p<0.001) with one procedure related death (3.2%). Renal function deteriorated without TIPS but improved (p<0.001) within two weeks after TIPS (creatinine clearance 18 (15) to 48 (42) ml/min; sodium excretion 9 (16) to 77 (78) mmol/24 hours) and stabilised thereafter. Following TIPS, three, six, 12, and 18 month survival rates were 81%, 71%, 48%, and 35%, respectively. As only 10% of non-shunted patients survived three months, total survival rates were 63%, 56%, 39%, and 29%, respectively. Multivariate Cox regression analysis revealed bilirubin (p<0.001) and HRS type (p<0.05) as independent survival predictors after TIPS.

Conclusions: TIPS provides long term renal function and probably survival benefits in the majority of non-transplantable cirrhotics with HRS. These data warrant controlled trials evaluating TIPS in the management of HRS.

Citing Articles

CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PORTAL HYPERTENSION.

Grgurevic I, Filipec Kanizaj T, Ivekovic H, Mikolasevic I, Milic S, Mrzljak A Acta Clin Croat. 2025; 63(1):214-243.

PMID: 39959335 PMC: 11827405. DOI: 10.20471/acc.2024.63.01.26.

Advances in the diagnosis and management of hepatorenal syndrome: insights into HRS-AKI and liver transplantation.

Arnold J, Avila E, Idalsoaga F, Diaz L, Ayala Valverde M, Ayares G eGastroenterology. 2025; 1(2):e100009.

PMID: 39943997 PMC: 11770447. DOI: 10.1136/egastro-2023-100009.

Effects of Transjugular Intrahepatic Portosystemic Shunt on Renal and Pulmonary Function in Hepatic Decompensation with and without Hepatorenal and Hepatopulmonary Syndromes: A Review.

Abdelwahed A, Aboeldahb M, Wu G J Clin Transl Hepatol. 2024; 12(9):780-791.

PMID: 39280072 PMC: 11393845. DOI: 10.14218/JCTH.2024.00188.

Attitudes towards transjugular intrahepatic portosystemic shunt (TIPS) in Australia: a national survey of TIPS centres.

Kalo E, Read S, George J, Roberts S, Majumdar A, Ahlenstiel G BMJ Open Gastroenterol. 2024; 11(1).

PMID: 38519047 PMC: 10966807. DOI: 10.1136/bmjgast-2023-001308.

Review on Kidney-Liver Crosstalk: Pathophysiology of Their Disorders.

Rad N, Heydari Z, Tamimi A, Zahmatkesh E, Shpichka A, Barekat M Cell J. 2024; 26(2):98-111.

PMID: 38459727 PMC: 10924833. DOI: 10.22074/cellj.2023.2007757.1376.

References

Koppel M, Coburn J, MIMS M, Goldstein H, Boyle J, RUBINI M . Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med. 1969; 280(25):1367-71. DOI: 10.1056/NEJM196906192802501. View

Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J . Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol. 1990; 11(2):153-8. DOI: 10.1016/0168-8278(90)90106-2. View

Gonwa T, Morris C, Goldstein R, Husberg B, Klintmalm G . Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients. Transplantation. 1991; 51(2):428-30. DOI: 10.1097/00007890-199102000-00030. View

Lenz K, Hortnagl H, Druml W, Reither H, Schmid R, Schneeweiss B . Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology. 1991; 101(4):1060-7. DOI: 10.1016/0016-5085(91)90734-3. View

Lang F, Tschernko E, Schulze E, Ottl I, Ritter M, Volkl H . Hepatorenal reflex regulating kidney function. Hepatology. 1991; 14(4 Pt 1):590-4. DOI: 10.1016/0270-9139(91)90043-u. View

Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K . Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med. 1992; 327(25):1774-8. DOI: 10.1056/NEJM199212173272502. View

Epstein M . The hepatorenal syndrome--newer perspectives. N Engl J Med. 1992; 327(25):1810-1. DOI: 10.1056/NEJM199212173272509. View

CONN H . Transjugular intrahepatic portal-systemic shunts: the state of the art. Hepatology. 1993; 17(1):148-58. View

Lake J, Ring E, Laberge J, Gordon R, Roberts J, Ascher N . Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency. Transplant Proc. 1993; 25(2):1766-7. View

10.

Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L . Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993; 105(1):229-36. DOI: 10.1016/0016-5085(93)90031-7. View

11.

Henriksen J, Ring-Larsen H . Hepatorenal disorders: role of the sympathetic nervous system. Semin Liver Dis. 1994; 14(1):35-43. DOI: 10.1055/s-2007-1007296. View

12.

Castells A, Salo J, Planas R, Quer J, Gines A, Boix J . Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology. 1994; 20(3):584-91. View

13.

Somberg K, Lake J, Tomlanovich S, Laberge J, Feldstein V, Bass N . Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology. 1995; 21(3):709-16. View

14.

Gerbes A, Moller S, Gulberg V, Henriksen J . Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology. 1995; 21(3):735-9. View

15.

Ochs A, Rossle M, Haag K, Hauenstein K, Deibert P, Siegerstetter V . The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med. 1995; 332(18):1192-7. DOI: 10.1056/NEJM199505043321803. View

16.

Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Zozaya J . Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology. 1995; 21(4):986-94. View

17.

Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L . Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med. 1995; 122(11):816-22. DOI: 10.7326/0003-4819-122-11-199506010-00002. View

18.

Sturgis T . Hepatorenal syndrome: resolution after transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol. 1995; 20(3):241-3. View

19.

DAmico G, Pagliaro L, Bosch J . The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995; 22(1):332-54. DOI: 10.1002/hep.1840220145. View

20.

Spahr L, Fenyves D, Nguyen V, Roy L, Legault L, Dufresne M . Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 1995; 90(7):1169-71. View